Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Active not recruiting

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05286060 2026-02-09

GENUINE

Phase 2 Active not recruiting

56 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02769520 2026-01-28

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Phase 2 Active not recruiting

27 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

Phase 2 Active not recruiting

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

36 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03546582 2026-01-20

KEYSTROKE

Phase 2 Active not recruiting

86 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05312710 2026-01-16

Safety and Efficacy of APG-157 in Head and Neck Cancer

Phase 2 Active not recruiting

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05522985 2026-01-13

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

122 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04141449 2025-12-31

Potlako+

Phase 2 Active not recruiting

874 enrolled

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Acquired Immunodeficiency Syndrome, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Neoplasms, Vulvar Neoplasms

NCT04831320 2025-12-30

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Phase 2 Active not recruiting

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00494182 2025-12-17

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

48 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

128 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03224000 2025-12-17

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

Phase 2 Active not recruiting

90 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT07267286 2025-12-05

Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）

Phase 2 Active not recruiting

60 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Phase 2 Active not recruiting

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2 Active not recruiting

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT04643379 2025-10-22

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Phase 2 Active not recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Phase 2 Active not recruiting

126 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05909904 2025-10-07

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

160 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05996523 2025-10-03

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Phase 2 Active not recruiting

16 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05044897 2025-09-26

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Phase 2 Active not recruiting

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05054439 2025-09-26

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Phase 2 Active not recruiting

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03070366 2025-09-02

OMET

Phase 2 Active not recruiting

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Phase 2 Active not recruiting

172 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04675294 2025-08-01

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Phase 2 Active not recruiting

189 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04609280 2025-07-29

SAVER

Phase 2 Active not recruiting

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Oropharyngeal Neoplasms

Clinical Trials

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Spark2

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

CACTUX

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

innovaTV 207

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

Rambro2

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

HNSCC

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

VELOCITY-HNSCC

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

GENUINE

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Pembrolizumab Plus Olaparib in LA-HNSCC

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

KEYSTROKE

Safety and Efficacy of APG-157 in Head and Neck Cancer

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Potlako+

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

OMET

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

SAVER